HCA Healthcare, Inc.
—- Market cap
- —
- Debt
- +$46.49B
- Cash
- −$1.04B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HCA stock price vs BA: inconclusive — current versus $2.40K implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BA's multiple
Implied fair value · at HCA's multiple
Needs HCA P/E.
Snapshot Sep 11, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 75% equity / 25% debt · EV / Revenue 2.34x · EV proxy / EBITDA proxy 33.61x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HCA Healthcare, Inc. · implied price per share
Bear
$130.81
Base
$187.37
Bull
$261.03
THE BOEING COMPANY · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LABCORP HOLDINGS INC.
HCA vs LH
WEST PHARMACEUTICAL SERVICES INC
HCA vs WST
BAXTER INTERNATIONAL INC
HCA vs BAX
MCKESSON CORP
HCA vs MCK
Cigna Group
HCA vs CI
UNITEDHEALTH GROUP INC
HCA vs UNH
LOCKHEED MARTIN CORP
HCA vs LMT
NORTHROP GRUMMAN CORP /DE/
HCA vs NOC
GENERAL DYNAMICS CORP
HCA vs GD
TEXTRON INC
HCA vs TXT
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HCA deserves a valuation closer to its DCF range and not the extreme BA BA multiple, then HCA looks attractive to own because it is cheaper on P/E, EV/EBITDA, and EV/Revenue while also showing stronger margins and lower leverage.
HCA trades at a large discount to BA across earnings and cash-flow proxies, with a P/E of 14.5x versus BA’s 91.3x and EV/EBITDA of 5.4x versus 47.3x. The current HCA price of $410.50 sits within its historical band but below both the DCF range and far below the BA BA-implied range.
Supporting Metrics